Stock Events

Amplify Treatments Testing and Advancements 

$18.96
14
-$0.03-0.16% Friday 18:54

Statistics

Day High
18.99
Day Low
18.99
52W High
20.1
52W Low
16.24
Volume
158
Avg. Volume
1,163
Mkt Cap
9.5M
P/E Ratio
0
Dividend Yield
1.86%
Dividend
0.35

Upcoming

27
SEP
Dividend Ex
Estimated
 
30
SEP
Dividend Payment
Estimated
 
27
DEC
Dividend Ex
Estimated
 
29
DEC
Dividend Payment
Estimated
 
26
MAR 25
Dividend Ex
Estimated
 
28
MAR 25
Dividend Payment
Estimated
 
27
JUN 25
Dividend Ex
Estimated
 
28
JUN 25
Dividend Payment
Estimated
 
20
SEP 25
Dividend Ex
Estimated
 
22
SEP 25
Dividend Payment
Estimated
 

Dividends

1.86%Dividend Yield
Sep 24
$0.09
Jun 24
$0.09
Mar 24
$0.06
Dec 23
$0.05
Sep 23
$0.04
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
46.83%
1Y Growth
32.02%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GERM. It's not an investment recommendation.
Alphabet
72232
GOOGL
Apple
63213
AAPL
Microsoft
58863
MSFT
Amazon
54450
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap29.75B
Moderna, Inc. focuses on mRNA-based therapies, directly competing in the biotech space for treatments and vaccines, similar to GERM's focus on advanced treatments.
BioNTech
BNTX
Mkt Cap20.98B
BioNTech SE specializes in personalized immunotherapies, which overlaps with GERM's advancements in treatment technologies.
Pfizer
PFE
Mkt Cap164.39B
Pfizer Inc. has a broad portfolio in healthcare, including treatments and vaccines that compete with GERM's product offerings.
Novavax
NVAX
Mkt Cap1.98B
Novavax, Inc. is involved in the development of vaccines, competing in the same space as GERM's focus on treatment and prevention.
Gilead Sciences
GILD
Mkt Cap98.35B
Gilead Sciences, Inc. is known for its antiviral drugs, directly competing with GERM's advancements in treatments.
Regeneron Pharmaceuticals
REGN
Mkt Cap130.59B
Regeneron Pharmaceuticals, Inc. works on biopharmaceuticals, including treatments that could rival GERM's innovative therapies.
Abbvie
ABBV
Mkt Cap346.75B
AbbVie Inc. operates in the pharmaceuticals sector, with a focus on advanced therapies that could compete with GERM's product line.
Johnson & Johnson
JNJ
Mkt Cap399.26B
Johnson & Johnson has a diverse healthcare portfolio, including pharmaceuticals that could compete with GERM's treatments.
AMGEN
AMGN
Mkt Cap179.38B
Amgen Inc. focuses on human therapeutics, which could compete with GERM's advancements in treatment technologies.
Astrazeneca
AZN
Mkt Cap271.67B
AstraZeneca PLC has a wide range of pharmaceutical products, including treatments and vaccines that could compete with GERM's offerings.

About

Miscellaneous
Investment Trusts/Mutual Funds
The index tracks the performance of U.S.-listed equity securities or depositary receipts of companies that (i) perform research, development, and commercialization of treatments or vaccines for infectious diseases or (ii) engage in the research, development, manufacturing, and provision of biological tests for patients. The fund invests at least 80% of its total assets in the component securities of the index. The fund is non-diversified.
Show more...
CEO
Country
US
ISIN
US26924G7631

Listings

ARCX
US
GERM